A Phase II Trial of Oxaliplatin and Capecitabine in the Treatment of Patients With Relapsed/Refractory Carcinoma of Unknown Primary Site
Upon determination of eligibility, patients will be receive:
- Oxaliplatin + Capecitabine
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response rate
18 months
No
John D. Hainsworth, MD
Principal Investigator
Sarah Cannon Research Institute
United States: Institutional Review Board
SCRI UNKPRI 14
NCT00193609
September 2004
January 2009
Name | Location |
---|---|
Spartanburg Regional Medical Center | Spartanburg, South Carolina 29303 |
Consultants in Blood Disorders and Cancer | Louisville, Kentucky 40207 |
Baton Rouge General Medical Center | Baton Rouge, Louisiana 70821-2511 |
Integrated Community Oncology Network | Jacksonville Beach, Florida 32250 |
Tennessee Oncology, PLLC | Clarksville, Tennessee 37043 |
Oncology Hematology Care | Cincinnati, Ohio 45242 |
Chattanooga Oncology Hematology Associates | Chattanooga, Tennessee 37404 |
Reading Hospital Regional Cancer Center | West Reading, Pennsylvania 19612 |
AP&S Oncology & Hematology Northside | Terre Haute, Indiana 47804 |
Greenview Regional Hospital | Bowling Green, Kentucky 42104 |